Drug Profile


Alternative Names: IP 2105; ISIS 2105

Latest Information Update: 25 Jan 1996

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Class Antivirals; Nucleosides
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Human papillomavirus infections

Most Recent Events

  • 25 Jan 1996 Discontinued-Preclinical for Cancer in USA (Unknown route)
  • 23 Jan 1996 Discontinued-II for Human papillomavirus infections in USA (Intralesional)
  • 08 Mar 1995 A clinical study has been added to the pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top